The American Heart Association annual conference in Philadelphia showcased groundbreaking scientific discoveries that have the potential to revolutionize the treatment of heart disease. Among the most notable were pioneering treatments that “rewrite” DNA, potentially offering permanent solutions to curb the body’s production of harmful cholesterol and reduce high blood pressure—two significant risk factors for heart attacks and strokes. These advancements represent a significant stride toward potential cures for heart disease.
Initially, due to uncertainties around potential side effects, these groundbreaking treatments that “rewrite” DNA will likely be reserved for individuals with the most severe diseases and urgent medical needs. However, if these treatments prove to be safe and effective, there is hope that they could revolutionize the landscape of cardiovascular care. If successful, these therapies might replace the daily intake of conventional medications like statins, blood thinners, and beta blockers, which millions currently use to reduce their risk of heart disease. The potential for such treatments could mark a transformative shift in cardiovascular medicine.
Los Angeles-based cardiologist Professor Karol Watson summed up the mood: ‘I cannot emphasise enough how revolutionary these [therapies] are,’ she said. ‘We are delving into uncharted territory with entirely new therapeutic strategies, new molecules and new mechanisms. The American Heart Association
The recent groundbreaking discoveries in cardiovascular research have prompted a shift in perspective among experts. Professor Tim Chico, a top cardiology researcher at the British Heart Foundation, emphasized the transformative potential of these findings, stating, “Rather than managing cardiovascular events in later life, if given early enough, these new approaches offer hope of curing cardiovascular disease.” With heart attacks accounting for 100,000 hospital admissions annually in England and heart disease causing one in four deaths, the prospect of revolutionary treatments offers hope for improved outcomes and potentially reducing the burden of cardiovascular conditions. The recent report on the twice-yearly jab zilebesiran, capable of reducing blood pressure by “switching off” a key gene, further underscores the potential impact of these advancements on reducing the risk of heart attacks and strokes.